PDK-1/Chk-1 inhibitors (Vernalis)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NamePDK-1/Chk-1 inhibitors (Vernalis)
Drug Alias Name3-phosphoinositide-dependent kinase-1/checkpoint kinase-1 inhibitors (Vernalis)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCheckpoint kinase 1 inhibitors3-phosphoinositide-dependent protein kinase 1 inhibitors
Targets3-phosphoinositide-dependent protein kinase 1Checkpoint kinase 1
Therapy Area/IndicationsAutoimmune DiseasesNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesVernalis Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesVernalis Plc
Active IndicationsN/A
Inactive IndicationsAutoimmune DiseasesNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A